KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 07/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -21.28% | -33.38% | -40.10% | -34.53% | -16.37% |
| Gross Profit | 182.12% | 123.64% | 56.35% | 36.05% | 16.37% |
| SG&A Expenses | 85.07% | 95.03% | 106.05% | 118.00% | 99.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.57% | 35.42% | 25.71% | 26.35% | 28.41% |
| Operating Income | 21.70% | 6.48% | -16.78% | -25.44% | -28.41% |
| Income Before Tax | 17.60% | 1.85% | -28.66% | -33.23% | -35.32% |
| Income Tax Expenses | -132.78% | -65.56% | -- | -- | -- |
| Earnings from Continuing Operations | 23.04% | 3.42% | -37.02% | -40.74% | -42.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.04% | 3.42% | -37.02% | -40.74% | -42.03% |
| EBIT | 21.70% | 6.48% | -16.78% | -25.44% | -28.41% |
| EBITDA | 22.12% | 6.79% | -16.78% | -25.51% | -28.50% |
| EPS Basic | 28.87% | 14.86% | -10.24% | -9.21% | -6.36% |
| Normalized Basic EPS | 24.30% | 13.90% | -3.60% | -3.41% | -1.34% |
| EPS Diluted | 28.87% | 14.86% | -10.24% | -9.21% | -6.36% |
| Normalized Diluted EPS | 24.30% | 13.90% | -3.60% | -3.41% | -1.34% |
| Average Basic Shares Outstanding | 9.38% | 14.06% | 24.51% | 29.34% | 34.78% |
| Average Diluted Shares Outstanding | 9.38% | 14.06% | 24.51% | 29.34% | 34.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |